



amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO:6, or a portion thereof having glucosyltransferase activity.



22. (Amended) A compound comprising a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO:6, or a portion thereof, the compound having (i) a glucosyltransferase activity domain, and (ii) a target cell specific binding domain which permits the compound to bind to a target cell.

23. (Amended) A compound comprising a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) as defined by SEQ ID NO:6, or a portion thereof, the compound having (i) a glucosyltransferase activity domain, (ii) a target cell specific binding domain, which domain causes the compound to bind to a target cell, and (iii) a translocation domain for translocating a catalytic domain of *Clostridium sordellii* lethal Toxin (LT) from the exterior of a cell into the interior of said cell.

24. (Amended) The compound according to claim 23, wherein the translocation domain consists essentially of approximately the N-terminal amino acids 1021-1700 of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT).



25. (Amended) The compound according to one of claims 22 to 24, wherein the target cell specific binding domain is an antibody or an antigen binding fragment thereof.

Supp
C4

27. (Amended) The composition comprising a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.